Vasogen to Conduct Year-end 2007 Conference Call
11 Janeiro 2008 - 1:00PM
PR Newswire (US)
MISSISSAUGA, ON, Jan. 11 /PRNewswire-FirstCall/ -- Vasogen Inc.
(NASDAQ:VSGN; TSX:VAS), a biotechnology Company focused on the
research and commercial development of technologies targeting the
chronic inflammation underlying cardiovascular and neurological
disease, will release its year-end results at 4:10 p.m. on
Wednesday, January 16, 2008. A conference call will follow at 4:30
p.m. Eastern Time, during which management will provide a Company
update and discuss year-end results. To participate via webcast,
please go to http://www.vasogen.com/. To participate by telephone,
please connect 10 minutes prior to the call to one of the
following: -------------------------------- Direct Dial
416-641-6142 -------------------------------- Toll-free
1-866-542-4241 -------------------------------- A re-broadcast of
the conference call will be available at http://www.vasogen.com/
and may also be accessed by: --------------------------------
Direct Dial 416-695-5800 -------------------------------- Toll-free
1-800-408-3053 -------------------------------- Passcode 3248350
-------------------------------- About Vasogen: Vasogen is a
biotechnology company engaged in the research and commercial
development of therapies designed to target the destructive
inflammatory process associated with the development and
progression of cardiovascular and neurodegenerative disorders. The
Company's lead product, the Celacade(TM) System, is designed to
activate the immune response to apoptosis - an important
physiological process that regulates inflammation. Celacade has
received European regulatory approval under the CE Mark for chronic
heart failure and is being marketed in the EU by Grupo Ferrer
Internacional, S.A. Celacade is also in late-stage clinical
development for the treatment of chronic heart failure in the
United States. Vasogen is also developing a new class of drugs for
the treatment of certain neuro-inflammatory disorders. VP025 is the
lead drug candidate from this new class. Certain statements
contained in this press release, the upcoming conference call and
webcast, or elsewhere in our public documents constitute
"forward-looking statements" within the meaning of the United
States Private Securities Litigation Reform Act of 1995 and/or
"forward-looking information" under the Securities Act (Ontario).
These statements may include, without limitation, plans to advance
the development of Celacade(TM) or VP025, plans to fund our current
activities, statements concerning our partnering activities, health
regulatory submissions, strategy, future operations, future
financial position, future revenues and projected costs. In some
cases, you can identify forward-looking statements by terminology
such as "may", "will", "should", "expects", "plans", "anticipates",
"believes", "estimated", "predicts", "potential", "continue",
"intends", "could", or the negative of such terms or other
comparable terminology. We made a number of assumptions in the
preparation of these forward-looking statements, including
assumptions about the nature, size, and accessibility of the market
for Celacade in the treatment of chronic heart failure,
particularly in Europe, the regulatory approval process leading to
commercialization and the availability of capital on acceptable
terms to pursue the development of Celacade, and the feasibility of
additional trials. You should not place undue reliance on our
forward-looking statements which are subject to a multitude of
risks and uncertainties that could cause actual results, future
circumstances or events to differ materially from those projected.
These risks include, but are not limited to, the outcome of further
ongoing analysis of the ACCLAIM trial results, the requirement or
election to conduct additional clinical trials and the size and
design of any such trials, delays or setbacks in the regulatory
approval process, difficulties in the maintenance of existing
regulatory approvals, securing and maintaining corporate alliances,
the need for additional capital and the effect of capital market
conditions and other factors on capital availability, the potential
dilutive effects of any financing, risks associated with the
outcomes of our preclinical and clinical research and development
programs, the adequacy, timing, and results of our clinical trials,
competition, market acceptance of our products, the availability of
government and insurance reimbursements for our products, the
strength of intellectual property, reliance on partners,
subcontractors, and key personnel, losses due to fluctuations in
the U.S.-Canadian exchange rate, and other risks detailed from time
to time in our public disclosure documents or other filings with
the Canadian and U.S. securities commissions or other securities
regulatory bodies. Additional risks and uncertainties relating to
our Company and our business can be found in the "Risk Factors"
section of our Annual Information Form and Form 20-F for the year
ended November 30, 2006, as well as in our later public filings.
The forward-looking statements are made as of the date hereof, and
we disclaim any intention and have no obligation or responsibility,
except as required by law, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise. DATASOURCE: Vasogen Inc. CONTACT: Glenn Neumann,
Investor Relations, 2505 Meadowvale Boulevard, Mississauga, ON,
Canada, L5N 5S2, tel: (905) 817-2004, fax: (905) 569-9231,
http://www.vasogen.com/,
Copyright